PHARMACY MARKET

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Everest Medicines | September 23, 2021

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
AbCellera and Everest Medicines Limited announced that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest’s portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology.

We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond, We believe our full-stack discovery engine, combined with Everest’s clinical development capabilities, creates synergy and the opportunity to speed the delivery of therapies to patients around the world.

- Carl Hansen, Ph.D., CEO and President of AbCellera.

By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access. The collaboration will leverage the full breadth of AbCellera’s technology stack, including sourcing fully humanized antibodies from the Trianni Mouse®, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform.

This collaboration will allow us to gain access to AbCellera’s cutting edge, AI-powered antibody discovery platform, which will greatly accelerate and increase the efficiency of our internal discovery efforts.

- Jennifer Yang, Ph.D., Chief Scientific Officer of Everest Medicines.

Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations in Asia and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of ten potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases.

About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

Spotlight

Theme 2 examines the trends in this rapidly evolving field. It will examine the regulatory challenges posed by these novel combination therapies, particularly the use of the biologics used in drug / device combinations. It will also consider the regulatory aspects of how information technology and health apps collect and use the data generated by modern medical devices. How can we ensure we that have a regulatory environment capable of reacting quickly to the needs of this dynamic sector and maximizing its benefits for the patient? The theme will also provide the latest news on the upcoming European Medical Device Regulation and In Vitro Diagnostic Regulation, highlight the latest trends in international medical device regulation and analyse consequences of the future European legislative changes for substance-based medical devices.

Related News

BUSINESS INSIGHTS

Corval™ Launches New Biopharma Commercialization Planning Platform

Corval | September 22, 2021

Corval LLC announced the launch of its cloud-based commercialization planning platform designed for early- to mid-stage biopharma companies. Created by industry veterans with deep experience in biopharma commercialization, the platform provides a technology-based approach that expedites the commercialization planning process and helps teams align on strategic decisions, timing, and future resourcing needs. I have spent my entire career in this space and been exposed to the many challenges facing early- to mid-stage biopharma companies, particularly, how the lack of in-house expertise and constrained resources can threaten the ability to know what to do when. - Sue Nemetz, founder and CEO of Corval and CEO of The NemetzGroup LLC, a strategic consultancy that has supported the progression of more than 100 companies with assets at every phase of development. As a biotech CEO and investor, I have seen many companies get mired in the commercialization planning process. Corval, built upon the wealth of knowledge and experience from The NemetzGroup, will help ensure biotech executive teams don't miss any critical steps on their path to market. - Abbie Celniker, Ph.D., a Partner at Third Rock Ventures. Corval's platform is built upon decades of biopharma commercialization experience and more than 75,000 data points that drive recommendations throughout the entire development timeline and accommodate the unique circumstances of each asset's commercial strategy. Corval contains foundational tools for commercialization success, including: Custom Commercialization Map: a detailed and adaptable roadmap of the objectives and activities necessary to commercialize an asset Budget and Resource Plan: a customized schedule of the resources and investments required to support these activities and achieve organizational objectives Commercialization Center: a single workspace to collaborate on the roadmap and access a trove of commercialization knowledge About Corval Corval develops technology solutions to empower biopharma leaders to navigate the commercialization process with confidence. Built on decades of commercialization expertise, its innovative cloud-based platform assesses each asset's unique situation and creates a customized, detailed map to illustrate every step on the journey from clinic to market. Corval reduces the commercialization planning process from three to six months to three to six days, dramatically streamlining efforts to set commercialization plans in motion.

Read More

Improved Pharma Continues to Expand Their Offerings to Meet Customer Needs

Improved Pharma | September 15, 2020

Improved Pharma has expanded their offerings by acquiring S. I. Photonics’ top-of-the-line spectrophotometer, model 440. This model has a high sensitivity, low noise CCD detector that enables the collection of a full spectrum within a second. The power of this instrument is enhanced by the number of accessories and dip probes that permit easy sampling of a variety of materials. The dip probes can be used to monitor reactions in real-time and are especially useful for obtaining quick data during dissolution experiments by placing the probe directly into the dissolution vessel. Dip probes of various path lengths (1 cm, 0.5 cm, and 0.2 cm) allow for the successful analysis of a wide range of solvents and concentrations. A standard cuvette holder can also be used. In addition to UV-Vis detection, HPLC is also available.

Read More

APhA: Transparency, Safety and Availability Must Be Core Principles for Strengthening America's Drug Supply Chain

APhA | August 11, 2020

The reliability, quality and safety of our nation's drug supply chain are essential to the nation's security and health and well-being of the American public. Therefore, we welcome comprehensive federal efforts to improve the state of our drug supply chain, particularly at a time when our health care system is under extraordinary stress. The President's Executive Order last week, "Ensuring Essential Medicines, Medical Countermeasures and Critical Inputs Are Made in the United States," is an important step forward, recognizing that available and safe medications and medical devices are essential to the health and well-being of our nation.

Read More

Spotlight

Theme 2 examines the trends in this rapidly evolving field. It will examine the regulatory challenges posed by these novel combination therapies, particularly the use of the biologics used in drug / device combinations. It will also consider the regulatory aspects of how information technology and health apps collect and use the data generated by modern medical devices. How can we ensure we that have a regulatory environment capable of reacting quickly to the needs of this dynamic sector and maximizing its benefits for the patient? The theme will also provide the latest news on the upcoming European Medical Device Regulation and In Vitro Diagnostic Regulation, highlight the latest trends in international medical device regulation and analyse consequences of the future European legislative changes for substance-based medical devices.